评估奥沙万星在各物种中的血清蛋白结合率。
Assessment of oritavancin serum protein binding across species.
机构信息
The Medicines Company, 7170 Frederick-Banting St., 2nd Floor, St. Laurent, Quebec H4S 2A1, Canada.
出版信息
Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.
Abstract
Biophysical methods to study the binding of oritavancin, a lipoglycopeptide, to serum protein are confounded by nonspecific drug adsorption to labware surfaces. We assessed oritavancin binding to serum from mouse, rat, dog, and human by a microbiological growth-based method under conditions that allow near-quantitative drug recovery. Protein binding was similar across species, ranging from 81.9% in human serum to 87.1% in dog serum. These estimates support the translation of oritavancin exposure from nonclinical studies to humans.
摘要
生物物理方法研究糖肽类药物奥他万古霉素与血清蛋白的结合时，会受到实验器具表面非特异性药物吸附的干扰。我们采用基于微生物生长的方法，在允许近乎定量回收药物的条件下，评估了奥他万古霉素与人、鼠、犬和狗血清的结合情况。在各物种中，蛋白结合情况相似，范围从人血清中的 81.9%到狗血清中的 87.1%。这些估计结果支持将非临床研究中的奥他万古霉素暴露量数据外推至人体。
相似文献
1
Assessment of oritavancin serum protein binding across species.
Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.
2
Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.
3
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Antimicrob Agents Chemother. 2013 Jan;57(1):205-11. doi: 10.1128/AAC.01428-12. Epub 2012 Oct 22.
4
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.
5
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01873-17. Print 2018 Jan.
6
Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.
J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17.
7
Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.
Antimicrob Agents Chemother. 2014 May;58(5):2921-4. doi: 10.1128/AAC.02482-13. Epub 2014 Feb 18.
8
Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.
Antimicrob Agents Chemother. 1998 Sep;42(9):2427-30. doi: 10.1128/AAC.42.9.2427.
9
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
10
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
Diagn Microbiol Infect Dis. 2017 Oct;89(2):168-171. doi: 10.1016/j.diagmicrobio.2017.06.023. Epub 2017 Jul 1.
引用本文的文献
1
Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
Clin Infect Dis. 2022 Oct 17;75(Suppl 3):S379-S391. doi: 10.1093/cid/ciac591.
2
Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences.
Antibiotics (Basel). 2022 Jul 8;11(7):923. doi: 10.3390/antibiotics11070923.
3
A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis.
Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):36-40. doi: 10.1007/s40801-020-00188-6.
4
Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01760-18. Print 2019 Jan.
5
Developments in Glycopeptide Antibiotics.
ACS Infect Dis. 2018 May 11;4(5):715-735. doi: 10.1021/acsinfecdis.7b00258. Epub 2018 Feb 19.
6
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an Pharmacokinetic/Pharmacodynamic Model of Infection.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01265-17. Print 2017 Oct.
7
Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.
Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5. doi: 10.1128/AAC.00981-15. Epub 2015 Aug 3.
8
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Antimicrob Agents Chemother. 2013 Jan;57(1):205-11. doi: 10.1128/AAC.01428-12. Epub 2012 Oct 22.
9
Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Clin Infect Dis. 2012 Apr;54 Suppl 3(Suppl 3):S233-8. doi: 10.1093/cid/cir924.
本文引用的文献
1
Significance of protein binding in pharmacokinetics and pharmacodynamics.
J Pharm Sci. 2010 Mar;99(3):1107-22. doi: 10.1002/jps.21916.
2
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
3
Nanomechanical detection of antibiotic-mucopeptide binding in a model for superbug drug resistance.
Nat Nanotechnol. 2008 Nov;3(11):691-6. doi: 10.1038/nnano.2008.275. Epub 2008 Oct 12.
4
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
Antimicrob Agents Chemother. 2008 Nov;52(11):3994-4000. doi: 10.1128/AAC.00427-08. Epub 2008 Sep 8.
5
Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Future Microbiol. 2008 Jun;3(3):251-63. doi: 10.2217/17460913.3.3.251.
6
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.
7
Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):441-4. doi: 10.1016/j.diagmicrobio.2007.11.011. Epub 2008 Jan 14.
8
In vitro studies on the impact of human serum on the antibacterial effect of faropenem.
J Chemother. 2004 Feb;16(1):23-9. doi: 10.1179/joc.2004.16.1.23.
9
Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.
Antimicrob Agents Chemother. 1998 Sep;42(9):2427-30. doi: 10.1128/AAC.42.9.2427.
10
Influence of binding on the pharmacologic activity of antibiotics.
Ann N Y Acad Sci. 1973 Nov 26;226:214-24. doi: 10.1111/j.1749-6632.1973.tb20483.x.
Zotero 插件